| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings CA Lipinski, F Lombardo, BW Dominy, PJ Feeney Adv. Drug Deliv. Rev 46 (1-3), 3, 2001 | 28522* | 2001 |
| Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings CA Lipinski, F Lombardo, BW Dominy, PJ Feeney Advanced drug delivery reviews 23, 3-25, 1997 | 28503 | 1997 |
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings CA Lipinski, F Lombardo, BW Dominy, PJ Feeney Advanced drug delivery reviews 64, 4-17, 2012 | 28477* | 2012 |
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings CA Lipinski, F Lombardo, BW Dominy, PJ Feeney Advanced drug delivery reviews 46 (1-3), 3-26, 2001 | 28477* | 2001 |
| Lead-and drug-like compounds: the rule-of-five revolution CA Lipinski Drug discovery today: Technologies 1 (4), 337-341, 2004 | 5474 | 2004 |
| Drug-like properties and the causes of poor solubility and poor permeability CA Lipinski Journal of pharmacological and toxicological methods 44 (1), 235-249, 2000 | 4353 | 2000 |
| Navigating chemical space for biology and medicine C Lipinski, A Hopkins Nature 432 (7019), 855-861, 2004 | 1237 | 2004 |
| Poor aqueous solubility—an industry wide problem in drug discovery C Lipinski Am. Pharm. Rev 5 (3), 82-85, 2002 | 1121 | 2002 |
| Rule of five in 2015 and beyond: Target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions CA Lipinski Advanced drug delivery reviews 101, 34-41, 2016 | 498 | 2016 |
| Avoiding investment in doomed drugs CA Lipinski Curr Drug Discov 1, 17-19, 2001 | 224 | 2001 |
| Chris Lipinski discusses life and chemistry after the Rule of Five CA Lipinski Drug discovery today 8 (1), 12-16, 2003 | 218 | 2003 |
| Bioisosterism in Drug Design CA Lipinski Annual Reports in Medicinal Chemistry 21, 283-291, 1986 | 206 | 1986 |
| Quantitative Structure−Activity Relationships among Macrolide Antibacterial Agents: In Vitro and in Vivo Potency against Pasteurella multocida JW McFarland, CM Berger, SA Froshauer, SF Hayashi, SJ Hecker, ... Journal of medicinal chemistry 40 (9), 1340-1346, 1997 | 177 | 1997 |
| A crowdsourcing evaluation of the NIH chemical probes TI Oprea, CG Bologa, S Boyer, RF Curpan, RC Glen, AL Hopkins, ... Nature chemical biology 5 (7), 441-447, 2009 | 140 | 2009 |
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Del. Rev. 46 (2001) 3–26 CA Lipinski, F Lombardo, BW Dominy, PJ Feeney Bulletin Technique Gattefossé ISSN, 0183-1224, 0 | 96 | |
| Badapple: promiscuity patterns from noisy evidence JJ Yang, O Ursu, CA Lipinski, LA Sklar, TI Oprea, CG Bologa Journal of cheminformatics 8, 1-14, 2016 | 94 | 2016 |
| Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis S Ekins, T Kaneko, CA Lipinski, J Bradford, K Dole, A Spektor, K Gregory, ... Molecular bioSystems 6 (11), 2316-2324, 2010 | 82 | 2010 |
| Polar molecular surface properties predict the intestinal absorption of drugs in humans CA Lipinski, F Lombardo, BW Dominy, PJ Feeney Adv. Drug Delivery Rev 46 (1-3), 3-26, 2001 | 82 | 2001 |
| Synthesis and antitubercular activity of 7-(R)-and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy) benzyloxy)-6, 7-dihydro-5H-imidazo [2, 1-b][1, 3] oxazines, analogues of PA-824 X Li, UH Manjunatha, MB Goodwin, JE Knox, CA Lipinski, TH Keller, ... Bioorganic & medicinal chemistry letters 18 (7), 2256-2262, 2008 | 80 | 2008 |
| High throughput sonication: evaluation for compound solubilization K Oldenburg, D Pooler, K Scudder, C Lipinski, M Kelly Combinatorial chemistry & high throughput screening 8 (6), 499-512, 2005 | 74 | 2005 |
Andrew L. HopkinsCEO, Exscientia在 exscientia.co.uk 的电子邮件经过验证
